Magle Chemoswed Holding AB (publ) (STO:MAGLE)

Market Cap	168.29M -74.3%
Revenue (ttm)	300.49M +43.6%
Net Income	-26.60M
EPS	-1.32
Shares Out	20.65M
PE Ratio	n/a
Forward PE	10.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	320
Average Volume	6,296
Open	7.95
Previous Close	8.15
Day's Range	7.90 - 8.15
52-Week Range	7.50 - 34.60
Beta	0.12
RSI	27.21
Earnings Date	Feb 27, 2026

About STO:MAGLE

Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson’s disease. The company also offers EmboCept S, a microsphere-based medical dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1944
• Employees: 144
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MAGLE

Financial Performance

In 2024, STO:MAGLE's revenue was 240.57 million, an increase of 40.27% compared to the previous year's 171.50 million. Earnings were 11.94 million, a decrease of -1.91%.